Alexandria Capital’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Alexandria Capital’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,000	Closed	-$299K	–	268
2021 Q2	$299K	Hold	8,000	–	–	0.03%	224
2021 Q1	$205K	Buy	+8,000	New	+$204K	0.02%	250
2020 Q3	–	Sell	-8,000	Closed	-$203K	–	246
2020 Q2	$203K	Buy	+8,000	New	+$172K	0.03%	229

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Alexandria Capital's DRNA Position: Q3 2021 in Review

Alexandria Capital sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 8,000 shares — an estimated $299K sold.

Alexandria Capital first reported a position in DRNA in Q2 2020 and held it in 3 quarters. The position peaked at $299K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Alexandria Capital reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Alexandria Capital sold 8,000 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $299K.
Alexandria Capital first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2020 and held it in 3 quarters.
Alexandria Capital's Dicerna Pharmaceuticals, Inc. position peaked at $299K in Q2 2021.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Alexandria Capital's 13F filing for Q3 2021, filed 2 Dec 2021.